MQS Management LLC Invests $255,000 in Enovis Co. (NYSE:ENOV)

MQS Management LLC bought a new stake in shares of Enovis Co. (NYSE:ENOV) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 5,645 shares of the company’s stock, valued at approximately $255,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Scout Investments Inc. acquired a new position in shares of Enovis during the first quarter valued at about $6,116,000. Price T Rowe Associates Inc. MD raised its stake in Enovis by 88.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after buying an additional 179,276 shares during the period. UBS Group AG boosted its holdings in Enovis by 1,060.8% in the fourth quarter. UBS Group AG now owns 333,510 shares of the company’s stock worth $18,683,000 after acquiring an additional 304,779 shares in the last quarter. Tributary Capital Management LLC grew its stake in Enovis by 15.6% in the first quarter. Tributary Capital Management LLC now owns 338,371 shares of the company’s stock valued at $21,131,000 after acquiring an additional 45,745 shares during the period. Finally, Quadrature Capital Ltd increased its holdings in shares of Enovis by 175.5% during the fourth quarter. Quadrature Capital Ltd now owns 34,160 shares of the company’s stock valued at $1,913,000 after acquiring an additional 21,760 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Evercore ISI reduced their price objective on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, Needham & Company LLC decreased their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and an average target price of $69.13.

Enovis Stock Performance

NYSE ENOV opened at $43.65 on Friday. The company has a fifty day moving average price of $44.73 and a 200-day moving average price of $50.05. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -29.10 and a beta of 1.92. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.26 and a quick ratio of 1.08. Enovis Co. has a 1 year low of $39.98 and a 1 year high of $65.03.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. During the same period in the prior year, the firm posted $0.61 EPS. The firm’s quarterly revenue was up 22.6% compared to the same quarter last year. As a group, equities research analysts predict that Enovis Co. will post 2.7 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.